Study identification

PURI

https://redirect.ema.europa.eu/resource/38431

EU PAS number

EUPAS7866

Study ID

38431

Official title and acronym

Post-approval observational prospective study to evaluate the prevalence of the metabolic syndrome in prostate cancer patients both before and after a 12-monthtreatment with quarterly LHRH analogue formulations (ANAMET Study)

DARWIN EU® study

No

Study countries

Spain

Study description

This post-approval observational prospective study assesses the prevalence of metabolic syndrome in men with prostate cancer before and after 12 months of treatment with quarterly Luteinizing-hormone-releasing hormone (LHRH) analogues formulations.

Study status

Finalised
Research institutions and networks

Institutions

Ipsen Pharma
First published:
01/02/2024
Institution
Multiple centres: 42 centres are involved in the study

Contact details

Medical Director, Uro-Oncology

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Ipsen
Study protocol
Initial protocol
English (463.88 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable